Results 61 to 70 of about 10,598 (216)

Recurrent SPECC1L–NTRK fusions in pediatric sarcoma and brain tumors [PDF]

, 2020
The identification of rearrangements driving expression of neurotrophic receptor tyrosine kinase (NTRK) family kinases in tumors has become critically important because of the availability of effective, specific inhibitor drugs.
Nagabushan, S, Hansford, JR, Kumar, A, Gifford, AJ, Brown, L.M., Ziegler, D.S., Wong-Erasmus, Marie, Fox, S.B., Kumar, A., Mayoh, C, Haber, M, Ludlow, L.E., Khuong-Quang, D.-A., Desai, J, Ekert, P.G., Marshall, GM, Khuong-Quang, DA, Sexton-Oates, A., Rodriguez, M, Sexton-Oates, A, Cowley, M.J., Desai, J., Cowley, MJ ; https://orcid.org/, Haber, M., Lau, L, Nagabushan, S., Rodriguez, M., Ekert, PG, Wong, M., Gifford, A.J., Pinese, M., Mayoh, C., Wong, M, Cowley, MJ, Ludlow, LE, Lau, L., Brown, LM, Marshall, G.M., Hansford, J.R., Pinese, M, Fox, SB, Ziegler, DS, Haber, M ; https://orcid.org/   +42 more
core   +1 more source

Central Nervous System Tumors Among Infants in Canada: A Report From CYP‐C

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Central nervous system (CNS) tumors in infants are rare, pose unique clinical challenges, and lack large‐scale evidence‐based data to guide management. This study seeks to describe CNS tumors in Canadian infants and to compare their outcomes with those of older children.
Samuel Sassine, Hallie Coltin, Sylvia Cheng, Lucie Lafay‐Cousin, Vanan Issai Magimairajan, Craig Erker, Stéphanie Vairy, Lynette Bowes, Adam Fleming, Donna Johnston, Sarah McKillop, Roona Sinha, Julie Bennett, Christina Coleman, Laura Wheaton, Shayna Zelcer, Samuele Renzi, Thai Hoa Tran   +17 more
wiley   +1 more source

Smoking status in patients with lung cancer from the overall, unselected NTRK⁻and NTRK⁺ cohorts.

, 2022
Abbreviations: FH-FMI CGDB, Flatiron Health–Foundation Medicine clinicogenomic database; NTRK-, neurotrophic tropomyosin receptor kinase fusion negative; NTRK+, neurotrophic tropomyosin receptor kinase fusion positive. (DOCX)
Solange Peters (318041), George D. Demetri (13215254), Laura Perez (3414401), Jessica Davies (3927101), Derrek P. Hibar (4502119), Olivier Humblet (2285017), Sophia L. Maund (11189433)   +6 more
core   +1 more source

Multidisciplinary consensus on optimising the detection of NTRK gene alterations in tumours [PDF]

, 2021
The recent identification of rearrangements of neurotrophic tyrosine receptor kinase (NTRK) genes and the development of specific fusion protein inhibitors, such as larotrectinib and entrectinib, have revolutionised the diagnostic and clinical management
Rojo, F, Garrido, P., Bautista, F, de-Alava, E, Colomer Bosch, Ramón, Colomer, R., Alvarez, R, Hladun, Raquel, de Álava, E., Garrido, P, Bautista, F., Hladun, R., López-Ríos, F., Garrido, Pilar, Colomer, R, Bautista, Francisco Jose, De Álava, Enrique, Álvarez, R., Álava Casado, Enrique de, Lopez-Rios, F, Álvarez, Rosa, Rojo, F., Universitat Autònoma de Barcelona, Hladun, R, de Álava, E, Colomer, Ramon   +25 more
core   +2 more sources

Chemotherapy for Spinal Cord Intramedullary Pediatric Low‐Grade Glioma—A Systematic Literature Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric intramedullary low‐grade gliomas (PIMLGGs) are rare neoplasms that present unique clinical and management challenges. Although surgery remains the primary tool for tissue diagnosis and decompression, complete gross‐total resection is frequently unfeasible due to the infiltrative nature of these lesions.
Olga M. Sergeenko, Segev Gabay, Jonathan Roth, Amit Ringel, Rina Dvir, Shlomi Constantini   +5 more
wiley   +1 more source

NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report

Frontiers in Oncology, 2023
Background: Neurotrophic tyrosine receptor kinase (NTRK) gene-fusion targeted molecules revolutionized the paradigm of treatment of a limited subgroup of cancers of various histologies.
Emanuela Palmerini, Giorgio Frega, Marco Gambarotti, Tommaso Frisoni, Marilena Cesari, Alberto Bazzocchi, Marco Miceli, Davide Maria Donati, Davide Maria Donati, Stefano Fanti, Cristina Nanni, Stefania Benini, Alessandra Longhi, Anna Paioli, Andrea Marrari, Rossella Hakim, Alberto Righi, Toni Ibrahim   +17 more
doaj   +1 more source

In vitro and in silico modelling of ROS1‐positive non‐small cell lung cancer reveals fusion‐dependent tyrosine kinase inhibitor responses

Molecular Oncology, EarlyView.
Drug resistance limits treatment success in a subset of lung cancers driven by ROS1 gene alterations. Using patient‐derived cells and computer simulations, we studied three key mutations and how they affect five targeted drugs. The mutations reduced drug effectiveness in different ways by altering protein structure and behavior.
Farhan Ul Haq, Marc Terrones, Felicia Rodrigues Fortes, Anne Schepers, Alessia Denis, Christophe Deben, Ken Op de Beeck, Guy Van Camp, Geert Vandeweyer   +8 more
wiley   +1 more source

Tumor Mutation Burden Survey of AACR GENIE Database Revealed NTRK (NTRK+) and RET (RET+) Fusions Positive Colorectal Carcinoma (CRC) as Distinct Subsets

Cancer Medicine
Background Receptor tyrosine kinase (RTK) inhibitors have been approved for the treatment of NTRK fusion (NTRK+) and RET fusion (RET+) positive solid tumors in a tumor‐agnostic manner. However, the objective response rate was the lowest among entrectinib‐
Zhaohui Liao Arter, Alexandria T. M. Lee, Misako Nagasaka, Sai‐Hong Ignatius Ou   +3 more
doaj   +1 more source

Pasta, a Versatile Transcriptomic Clock, Maps the Chemical and Genetic Determinants of Aging and Rejuvenation

Advanced Science, EarlyView.
Pasta is a transcriptomic aging clock built on an age‐shift learning framework and trained on 17 000 samples across 21 datasets. It accurately predicts relative biological age across tissues, platforms, and species, captures stemness‐to‐senescence transitions, and identifies age‐modulatory perturbations.
Jérôme Salignon, Maria Tsiokou, Patricia Marqués, Enriqueta Rodríguez‐Diaz, Hazel Ang, Federico Pietrocola, Christian G. Riedel   +6 more
wiley   +1 more source

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

Oncotarget, 2018
Merestinib is an oral multi-kinase inhibitor targeting a limited number of oncokinases including MET, AXL, RON and MKNK1/2. Here, we report that merestinib inhibits neurotrophic receptor tyrosine kinases NTRK1/2/3 which are oncogenic drivers in tumors bearing NTRK fusion resulting from chromosomal rearrangements.
Konicek, Bruce W., Capen, Andrew R., Credille, Kelly M., Ebert, Philip J., Falcon, Beverly L., Heady, Gary L., Patel, Bharvin K.R., Peek, Victoria L., Stephens, Jennifer R., Stewart, Julie A., Stout, Stephanie L., Timm, David E., Um, Suzane L., Willard, Melinda D., Wulur, Isabella H., Zeng, Yi, Wang, Yong, Walgren, Richard A., Betty Yan, Sau-Chi   +18 more
openaire   +3 more sources